Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma

Australas J Dermatol. 2022 Feb;63(1):e71-e74. doi: 10.1111/ajd.13704. Epub 2021 Aug 31.

Abstract

Pembrolizumab is a humanised therapeutic antibody against the PD-1 receptor. It has been used in various advanced cancer immunotherapies. Here, we report an extremely rare case of a 32-year-old man who developed Stevens-Johnson syndrome (SJS) with porokeratosis simultaneously during pembrolizumab treatment for primary hepatocellular carcinoma (T3N1M1).

Keywords: PD-1 inhibitor; Stevens-Johnson syndrome; immune checkpoint inhibitors; pembrolizumab; porokeratosis; toxic epidermal necrolysis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Carcinoma, Hepatocellular / drug therapy
  • Humans
  • Liver Neoplasms / drug therapy
  • Male
  • Porokeratosis / chemically induced*
  • Stevens-Johnson Syndrome / etiology*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab